Pravastatin Sodium

WILMINGTON, N.C., Dec. 18, 2025 /PRNewswire/ -- CardioPharma, Inc. (the "Company"), a specialty pharmaceutical company focused on combinatorial drug development for cardiovascular diseases, is seeking applications for secondary analyses of existing datasets to investigate the non-cardiovascular (non-CVD) benefits of the CVD polypill (3 or more medications). While the polypill (fixed-dose combination therapy) is primarily intended for CVD prevention and treatment, emerging evidence suggests potential broader health benefits. This funding opportunity invites investigators to explore these effects, determine how much is mediated by CVD improvements versus direct benefits, and evaluate outcomes in both primary and secondary prevention settings. Dr. Frank Snyder, Chief Medical Officer, stated, "the medical literature has researched and published extensively on the myriad benefits of cardiovascular polypills for years," continuing, "the primary benefits of adherence, safety and efficacy are well known – we want to push our understanding beyond that." Professor of Cardiovascular Medicine at Wake Forest University School of Medicine and CardioPharma Scientific Advisory Board member, Dr. Elsayed Soliman, notes, "Our interest is piqued by the broader potential benefits beyond traditional cardiovascular disease - extending to Alzheimer's disease and related dementias, cognitive decline, cerebral vascular disease including stroke, peripheral vascular disease, chronic kidney disease as well as, potentially, certain ophthalmologic conditions." "By formally commissioning research into these potential non-cardiovascular benefits, CardioPharma is seeking to expand the understanding of how combinatorial cardiovascular medications may benefit less traditional disease states," according to CFO Roy Stimits, "which could benefit an entire new group of patients." CardioPharma's Dr. Daniel Gregory continued, "the global need for these inexpensive medications delivered in a convenient and cost-effective polypill is great. Despite the limited availability in much of the world, this research may help expand patient access by demonstrating even greater need." CardioPharma is dedicated to bringing innovative cardiovascular fixed-dose combinations to markets around the world. Investigators are invited to apply starting February 15, 2026. Further information is available at: CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma, Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for physicians and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit cardiopharma.com or contact Dr. Daniel Gregory [email protected] Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. SOURCE CardioPharma, Inc. 21% more press release views with Request a Demo

– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous Thromboembolism Events Compared to Placebo – ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post hoc analyses from CLEAR Outcomes focused on: 1) risk of major adverse cardiovascular event in ~8200 patients receiving no background lipid lowering therapies (LLT) and 2) risk of venous thromboembolism (VTE) with bempedoic acid compared to placebo. These data were presented in oral and poster presentations, respectively, at the 2025 American Heart Association (AHA) Scientific Sessions, taking place November 7-10, 2025, in New Orleans, LA. “Bempedoic acid is a proven drug to reduce risk for adverse cardiovascular (CV) outcomes such as heart attack and stroke in patients who cannot take recommended statin therapy. The new data demonstrates the efficacy of bempedoic acid alone on reducing CV risk and suggests bempedoic acid may have benefits beyond preventing atherosclerosis by preventing deep venous thrombosis and pulmonary embolism,” said Luke Laffin, MD, senior author for these CLEAR Outcomes sub analyses, and Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. "These new analyses from CLEAR Outcomes continue to reinforce the clinical value of NEXLETOL as a foundational therapy for cardiovascular risk reduction, particularly in patients who are unable to tolerate statins," said Sheldon Koenig, President and Chief Executive Officer of Esperion. "The consistency of benefit seen with bempedoic acid monotherapy - both in lowering LDL-C and reducing major adverse cardiovascular events - underscores its potential to address a critical unmet need in preventive cardiology. We are proud to see this data presented at AHA, one of the most influential forums in cardiovascular medicine, and remain committed to advancing therapies that improve outcomes for patients worldwide." Key data presented at the 2025 AHA Scientific Sessions Bempedoic acid monotherapy, LDL cholesterol and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial presented by Carolina Pires Zingano, MD (Cleveland Clinic) Highlights Over half (59%) of the 13,970 participants in CLEAR Outcomes were not receiving any background LLT during the study. Compared with placebo, bempedoic acid monotherapy lowered LDL-C by -20.6% at 6 months and reduced MACE-4 (CV death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) by 14%. Safety that included total adverse events, serious adverse events and adverse events that led to study drug discontinuation were similar amongst patients on bempedoic acid or placebo. Compared with placebo, bempedoic acid monotherapy lowered LDL-C by -20.6% at 6 months and reduced MACE-4 (CV death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) by 14%. Safety that included total adverse events, serious adverse events and adverse events that led to study drug discontinuation were similar amongst patients on bempedoic acid or placebo. Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial presented by Bernardo Frison Spiazzi, MD (Cleveland Clinic) Highlights Treatment with bempedoic acid in patients with statin intolerance and at high risk for, or with established cardiovascular disease, was associated with a reduction in venous thromboembolic (VTE; deep vein or lung blood clots) events. In total, 106 VTE events occurred over 40.6 months of follow up. Compared with placebo, bempedoic acid reduced the risk of any VTE by 42% [risk of deep venous thrombosis (DVT) was reduced by 44% and pulmonary embolism (PE) by 39%]. In total, 106 VTE events occurred over 40.6 months of follow up. Compared with placebo, bempedoic acid reduced the risk of any VTE by 42% [risk of deep venous thrombosis (DVT) was reduced by 44% and pulmonary embolism (PE) by 39%]. INDICATION NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or at high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. established cardiovascular disease (CVD), or at high risk for a CVD event but without established CVD. IMPORTANT SAFETY INFORMATION NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. Concomitant use of NEXLETOL with greater than 20 mg of simvastatin or 40 mg of pravastatin should be avoided due to the potential for increased risk of simvastatin- or pravastatin-related myopathy. Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL. Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law. Esperion Contact Information: Investors: Alina Venezia investorrelations@esperion.com (734) 887-3903 Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438